Egypt welcomes 25-nation statement urging end to Gaza war    Egyptian pound ticks down in early Tuesday trading    FinMin: Egypt economy expands, budget surplus at record high    Egypt, Senegal sign pharma MoU to unify regulatory standards    Famine kills more Gaza children as Israel tightens siege amid global outrage    Kuwait's Crown Prince, Egyptian minister discuss strengthening cooperation    Egypt's FM seeks deeper economic, security ties on five-nation West Africa tour    Egyptian Drug Authority discusses plans for joint pharmaceutical plant in Zambia    Madbouly reviews legalisation of newly annexed lands to new cities, housing offerings    Egyptian Countryside Development chief discusses cooperation with Italian ambassador    CIB completes fifth securitisation issuance for B.TECH worth EGP 859.4m    Roche helps Egypt expand digital pathology and AI diagnostics    Two militants killed in foiled plot to revive 'Hasm' operations: Interior ministry    Egypt exports 175K tons of food in one week    Egypt foils terrorist plot, kills two militants linked to Hasm group    Egypt, Somalia discuss closer environmental cooperation    Egypt's Health Minister reviews upgrades at Gustave Roussy Hospital    Giza Pyramids' interior lighting updated with new LED system    Egypt's EHA, Huawei discuss enhanced digital health    Egypt expresses condolences to Iraq over fire tragedy    Foreign, housing ministers discuss Egypt's role in African development push    Korea Culture Week in Egypt to blend K-Pop with traditional arts    CIB finances Giza Pyramids Sound and Light Show redevelopment with EGP 963m loan    Egypt, Uruguay eager to expand trade across key sectors    Egypt reveals heritage e-training portal    Three ancient rock-cut tombs discovered in Aswan    Sisi launches new support initiative for families of war, terrorism victims    Egypt expands e-ticketing to 110 heritage sites, adds self-service kiosks at Saqqara    Egypt's Irrigation Minister urges scientific cooperation to tackle water scarcity    Palm Hills Squash Open debuts with 48 international stars, $250,000 prize pool    Egypt's Democratic Generation Party Evaluates 84 Candidates Ahead of Parliamentary Vote    On Sport to broadcast Pan Arab Golf Championship for Juniors and Ladies in Egypt    Golf Festival in Cairo to mark Arab Golf Federation's 50th anniversary    Germany among EU's priciest labour markets – official data    Paris Olympic gold '24 medals hit record value    A minute of silence for Egyptian sports    Russia says it's in sync with US, China, Pakistan on Taliban    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Trial of COVID-19 blood plasma finds no benefit in severely ill patients
Published in Ahram Online on 11 - 01 - 2021

An international trial testing convalescent blood plasma in cases of moderate and severe COVID-19 has halted enrolment of severely ill patients requiring intensive care after finding the plasma was of no benefit, trial investigators said on Monday.
The decision by the REMAP-CAP trial leaders came after an initial analysis of more than 900 severely ill trial participants in intensive care showed that treatment with the product - an antibody-rich plasma taken from people who have recovered from the pandemic disease - did not improve outcomes.
"There was no evidence of harm associated with the administration of convalescent plasma" (and) the trial is continuing to recruit hospitalised COVID-19 patients who are moderately ill but not in intensive care, scientists leading the trial said in a statement.
"It is biologically plausible that patients who are not producing antibodies at the time of convalescent plasma therapy and those patients with excess virus may benefit more than others. Our additional analyses will explore this," said Manu Shankar-Hari, a clinician and professor of critical care medicine at Britain's Guy's and St Thomas' hospital, who is co-leading the trial.
He added that the initial analysis did not assess plasma's effects in hospitalised patients with less severe disease. This "remains a very important question" and would continue to be explored in the ongoing trial, he said.
The underlying hypothesis for using convalescent plasma as a potential treatment for COVID-19 patients is that the antibodies it contains could neutralize the virus, stopping it from replicating and halting tissue damage.
Smaller studies of convalescent plasma in COVID-19 patients in India and in Argentina have also found no apparent benefit for those critically or severely ill with the disease.
The analysis leading to the REMAP-CAP pause in enrolment of critically ill patients showed there was a very low probability - 2.2% - that it reduced death rates or decreased the number of days patients needed intensive care.
"Why convalescent plasma does not seem to improve outcome in severely ill COVID-19 patients admitted to the ICU is not yet known. However, it may be because the lung damage is too advanced for convalescent plasma to make a difference," said Alexis Turgeon, a critical care doctor and professor at Université Laval in Canada, who is also working on the trial.
But scientists and doctors called for convalescent plasma trials to continue and for recovered COVID-19 patients to continue to donate their blood in the hope it might help others.
"Antibodies work by stopping the virus, not by treating the symptoms," said Gail Miflin, a medical expert in the blood and transplant unit of the UK National Health Service. "The emerging evidence from international studies is that use before intensive care may prove to be more effective."
REMAP-CAP is an international clinical trial exploring a range of potential treatments for COVID-19. It has already recruited 4,100 COVID-19 patients for convalescent plasma trials at more than 290 clinical sites across Europe, the Americas, Asia, Africa and Australasia.
Separate findings from REMAP-CAP showed last week that treating critically ill COVID-19 patients with Roche's Actemra or Sanofi's Kevzara arthritis drugs significantly improved survival rates and reduced the amount of time patients need intensive care.


Clic here to read the story from its source.